Targeting CCR5 trafficking to inhibit HIV-1 infection
暂无分享,去创建一个
P. Gestraud | F. Perez | M. Fukata | Y. Fukata | Gaelle Boncompain | A. Brelot | I. Staropoli | Aurianne Lescure | E. Del Nery | F. Herit | F. Niedergang | Sarah Tessier
[1] Yunchao Su,et al. The GTPase Rab43 Controls the Anterograde ER-Golgi Trafficking and Sorting of GPCRs , 2017, Cell reports.
[2] Nir Hacohen,et al. A genome-wide CRISPR screen identifies a restricted set of HIV host dependency factors , 2016, Nature Genetics.
[3] F. Perez,et al. Microtubule-independent secretion requires functional maturation of Golgi elements , 2016, Journal of Cell Science.
[4] S. Zhang,et al. The Cysteine-rich Domain of the DHHC3 Palmitoyltransferase Is Palmitoylated and Contains Tightly Bound Zinc* , 2015, The Journal of Biological Chemistry.
[5] R. Qiu,et al. Cadmium-zinc exchange and their binary relationship in the structure of Zn-related proteins: a mini review. , 2014, Metallomics : integrated biometal science.
[6] Wei-Ting Hwang,et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. , 2014, The New England journal of medicine.
[7] F. Perez,et al. The many routes of Golgi-dependent trafficking , 2013, Histochemistry and Cell Biology.
[8] Franck Perez,et al. Synchronization of secretory protein traffic in populations of cells , 2012, Nature Methods.
[9] D. Dupré,et al. Dependence on different Rab GTPases for the trafficking of CXCR4 and CCR5 homo or heterodimers between the endoplasmic reticulum and plasma membrane in Jurkat cells. , 2011, Cellular signalling.
[10] M. Churchill,et al. HIV-1 Escape from the CCR5 Antagonist Maraviroc Associated with an Altered and Less-Efficient Mechanism of gp120-CCR5 Engagement That Attenuates Macrophage Tropism , 2011, Journal of Virology.
[11] F. Bushman,et al. A Maraviroc-Resistant HIV-1 with Narrow Cross-Resistance to Other CCR5 Antagonists Depends on both N-Terminal and Extracellular Loop Domains of Drug-Bound CCR5 , 2010, Journal of Virology.
[12] S. Benichou,et al. Inhibition of phagocytosis in HIV-1-infected macrophages relies on Nef-dependent alteration of focal delivery of recycling compartments. , 2010, Blood.
[13] E. Thiel,et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. , 2009, The New England journal of medicine.
[14] E. Thiel,et al. Long-Term Control of HIV by CCR 5 Delta 32 / Delta 32 Stem-Cell Transplantation , 2009 .
[15] Amy S. Espeseth,et al. Genome-scale RNAi screen for host factors required for HIV replication. , 2008, Cell host & microbe.
[16] R. Redfield,et al. Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults. , 2008, The Journal of infectious diseases.
[17] R. König,et al. Global Analysis of Host-Pathogen Interactions that Regulate Early-Stage HIV-1 Replication , 2008, Cell.
[18] J. Orange,et al. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases , 2008, Nature Biotechnology.
[19] C. Jean,et al. Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in the US epidemic. , 2008, The Journal of infectious diseases.
[20] Å. Lundkvist,et al. A deletion in the chemokine receptor 5 (CCR5) gene is associated with tickborne encephalitis. , 2008, The Journal of infectious diseases.
[21] J. Lieberman,et al. Identification of Host Proteins Required for HIV Infection Through a Functional Genomic Screen , 2007, Science.
[22] D. McDermott,et al. CCR5 deficiency increases risk of symptomatic West Nile virus infection , 2006, The Journal of experimental medicine.
[23] David A. Price,et al. Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity , 2005, Antimicrobial Agents and Chemotherapy.
[24] Michael S Saag,et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1 , 2005, Nature Medicine.
[25] Hillel Adesnik,et al. Identification of PSD-95 Palmitoylating Enzymes , 2004, Neuron.
[26] C. Raggi,et al. Mini review , 2004 .
[27] W. Greene,et al. A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes , 2002, Nature Biotechnology.
[28] Y. Percherancier,et al. Palmitoylation-dependent Control of Degradation, Life Span, and Membrane Expression of the CCR5 Receptor* , 2001, The Journal of Biological Chemistry.
[29] R. Doms,et al. Palmitoylation of CCR5 Is Critical for Receptor Trafficking and Efficient Activation of Intracellular Signaling Pathways* , 2001, The Journal of Biological Chemistry.
[30] A. Trkola,et al. Potent, Broad-Spectrum Inhibition of Human Immunodeficiency Virus Type 1 by the CCR5 Monoclonal Antibody PRO 140 , 2001, Journal of Virology.
[31] T. Nakashima,et al. Tetrocarcin A inhibits mitochondrial functions of Bcl-2 and suppresses its anti-apoptotic activity. , 2000, Cancer research.
[32] Kuan-Teh Jeang,et al. Mechanism of Transdominant Inhibition of CCR5-mediated HIV-1 Infection by ccr5Δ32* , 1997, The Journal of Biological Chemistry.
[33] N. Heveker,et al. Identification of a chemokine receptor encoded by human cytomegalovirus as a cofactor for HIV-1 entry. , 1997, Science.
[34] Marc Parmentier,et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene , 1996, Nature.
[35] Richard A Koup,et al. Homozygous Defect in HIV-1 Coreceptor Accounts for Resistance of Some Multiply-Exposed Individuals to HIV-1 Infection , 1996, Cell.
[36] C. Broder,et al. CC CKR5: A RANTES, MIP-1α, MIP-1ॆ Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1 , 1996, Science.
[37] Marc Parmentier,et al. A Dual-Tropic Primary HIV-1 Isolate That Uses Fusin and the β-Chemokine Receptors CKR-5, CKR-3, and CKR-2b as Fusion Cofactors , 1996, Cell.
[38] Ying Sun,et al. The β-Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 Isolates , 1996, Cell.
[39] Virginia Litwin,et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5 , 1996, Nature.
[40] Stephen C. Peiper,et al. Identification of a major co-receptor for primary isolates of HIV-1 , 1996, Nature.
[41] J. Lippincott-Schwartz,et al. Golgi dispersal during microtubule disruption: regeneration of Golgi stacks at peripheral endoplasmic reticulum exit sites. , 1996, Molecular biology of the cell.
[42] F. Wurm,et al. Transfecting mammalian cells: optimization of critical parameters affecting calcium-phosphate precipitate formation. , 1996, Nucleic acids research.
[43] P. Charneau,et al. Fusion from without directed by human immunodeficiency virus particles , 1994, Journal of virology.
[44] J. Lippincott-Schwartz,et al. Rapid redistribution of Golgi proteins into the ER in cells treated with brefeldin A: Evidence for membrane cycling from Golgi to ER , 1989, Cell.
[45] T. Tamaoki,et al. TETROCARCINS, NOVEL ANTITUMOR ANTIBIOTICS , 1980 .
[46] T. Tamaoki,et al. Tetrocarcins, novel antitumor antibiotics. I. Producing organism, fermentation and antimicrobial activity. , 1980, The Journal of antibiotics.